Particula | $5,500,000 | (May 1, 2025)
Stimuler | $3,750,000 | (May 1, 2025)
SpriveApp | $7,300,000 | (May 1, 2025)
Certified by Founder
Lodge
DalCor Pharmaceuticals
start up
Canada
- Montreal, Québec
- 22/09/2023
- Series D
- $80,000,000
DalCor Pharmaceuticals: DalCor Pharmaceuticals is pioneering precision medicine for patients with cardiovascular disease. By combining genetic and clinical insights, the company’s development program, dalcetrapib, is intended to reduce fatal and non-fatal myocardial infarction (MI) following a recent acute coronary syndrome and deliver superior cardiovascular outcome in a specific genetic subset of patients.
- Industry Biotechnology Research
- Website https://dalcorpharma.com/
- LinkedIn https://www.linkedin.com/company/dalcor-pharmaceuticals/about/
Manifest | $15,000,000 | (May 1, 2025)
Spark Biomedical Inc | $15,000,000 | (May 1, 2025)
Queens Carbon | $10,000,000 | (May 1, 2025)
Noma Therapy | $4,250,000 | (May 1, 2025)
Persona | $200,000,000 | (May 1, 2025)
Nuvo | $45,000,000 | (May 1, 2025)
Pallie | $2,000,000 | (May 1, 2025)
Faye(US) | $2,500,000 | (May 1, 2025)
Structify | $4,100,000 | (May 1, 2025)